Project 1: Co-Targeting ER and Kinome Deregulation in Breast Cancers with Neurofibromin Deficiency

项目 1:联合靶向 ER 和激酶组失调治疗神经纤维蛋白缺乏的乳腺癌

基本信息

  • 批准号:
    10460212
  • 负责人:
  • 金额:
    $ 33.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-19 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Over 250,000 cases of breast cancer are diagnosed annually in the US alone, and about 80% of these will be estrogen receptor-α positive (ER+). Despite great progress in treating this ER+ disease by endocrine therapy, resistanceto this treatment remains a major problem, causing the majority of deaths from breast cancer. Our clinical studies on resistance have found that inactivation of the NF1 (for neurofibromatosis type 1) gene, which may occur in as much as 20% of primary ER+ breast cancer patients, correlates with a poor outcome in tamoxifen-treated patients. NF1 encodes neurofibromin, best known as a Ras repressor (a GTPase Activating Protein, or GAP), but the scie ntific premise of this project stems from our discovery that besides activating Ras, loss of NF1 also globally enhances estradiol (E2)-dependent gene expression, thus permitting the cells to grow in lower levels of E2 or even in tamoxifen, because NF1 also directly interacts with ER as a transcriptional co- repressor. In contrast to their lack of response to E2-deprivation or tamoxifen treatment, NF1-depleted cells still respond to fulvestrant, a SERD (Selective ER Degrader), and although the reduced repression of Ras-Raf signaling in NF1-depleted cells still allows promotion of cell survival/growth, this in turn could be blocked pharmacologically by FDA-approved kinase inhibitors. This project will therefore investigate the hypothesis that NF1-deficient ER+ breast tumors should be treated by a SERD together with inhibitors bloc king the Ras-Raf pathway. To assess whether NF1-status in patient tumors can differentiate treatment responses to various endocrine agents, Aim 1 will first establish an effective diagnosis for NF1-deficiency and then analyze how NF1- status impacts long-term treatment responses in two large randomized neoadjuvant clinical trials, ALTERNATE and P024. The former compares fulvestrant vs. AI (anastrozole), while the latter compares tamoxifen vs. another AI (letrozole). In addition, we propose that NF1-deficient ER+ breast cancer should be treated by a SERD combined with kinase inhibitors targeting the Ras-Raf pathway, so that Aim 2 will conduct preclinical modeling to examine new generation oral SERDs and Ras effector kinase inhibitors to find the best combination to drive clinical trial design and encourage pharma interest in trial support. A Phase -2 clinical trial to further this treatment concept has been planned, for which we already have pharma interest and commitment. We will support this trial here by developing technologies to assess how NF1-heterogeneity impacts treatment response. Finally, Aim 3 will analyze kinome reprograming after SERD treatment in primary NF1-deficient patients (Aim 1) and in preclinical models (Aim 2) by a mass spectrometry-based micro-scaled platform called KiP (Kinome Profiling). While our primary objective is to assess whether the use of a SERD in NF1 -depleted tumors can lead to compensatory Ras-Raf activation, the KiP platform is intrinsically unbiased and may also discover additional kinases driving SERD resistance. The successful execution of this project may stop the progression of the NF1- deficient subset of ER+ aggressive breast cancer early in its tracks.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW J ELLIS其他文献

MATTHEW J ELLIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW J ELLIS', 18)}}的其他基金

Translational Breast Cancer Research Training Program
转化乳腺癌研究培训计划
  • 批准号:
    9977965
  • 财政年份:
    2018
  • 资助金额:
    $ 33.98万
  • 项目类别:
Administration and Advocacy
行政及宣传
  • 批准号:
    10704511
  • 财政年份:
    2014
  • 资助金额:
    $ 33.98万
  • 项目类别:
Administration and Advocacy
行政及宣传
  • 批准号:
    10460206
  • 财政年份:
    2014
  • 资助金额:
    $ 33.98万
  • 项目类别:
Project 1: Co-Targeting ER and Kinome Deregulation in Breast Cancers with Neurofibromin Deficiency
项目 1:联合靶向 ER 和激酶组失调治疗神经纤维蛋白缺乏的乳腺癌
  • 批准号:
    10704529
  • 财政年份:
    2014
  • 资助金额:
    $ 33.98万
  • 项目类别:
PROTEOGENOMIC ANALYSIS OF HUMAN-IN-MOUSE BREAST CANCER XENOGRAFTS
人鼠乳腺癌异种移植物的蛋白质组学分析
  • 批准号:
    8361435
  • 财政年份:
    2011
  • 资助金额:
    $ 33.98万
  • 项目类别:
Breast Cancer Research
乳腺癌研究
  • 批准号:
    8181188
  • 财政年份:
    2010
  • 资助金额:
    $ 33.98万
  • 项目类别:
Biological Breast Cancer Classification by qRT-PCR
通过 qRT-PCR 进行乳腺癌生物学分类
  • 批准号:
    7913963
  • 财政年份:
    2009
  • 资助金额:
    $ 33.98万
  • 项目类别:
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY
用于芳香酶抑制剂治疗的新型生物标志物
  • 批准号:
    7953937
  • 财政年份:
    2009
  • 资助金额:
    $ 33.98万
  • 项目类别:
NOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPY
用于芳香酶抑制剂治疗的新型生物标志物
  • 批准号:
    7721520
  • 财政年份:
    2008
  • 资助金额:
    $ 33.98万
  • 项目类别:
Biological Breast Cancer Classification by qRT-PCR
通过 qRT-PCR 进行乳腺癌生物学分类
  • 批准号:
    7127620
  • 财政年份:
    2005
  • 资助金额:
    $ 33.98万
  • 项目类别:

相似海外基金

Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
  • 批准号:
    DP240100640
  • 财政年份:
    2024
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
  • 批准号:
    23K01889
  • 财政年份:
    2023
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10452217
  • 财政年份:
    2022
  • 资助金额:
    $ 33.98万
  • 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10670838
  • 财政年份:
    2022
  • 资助金额:
    $ 33.98万
  • 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
  • 批准号:
    DP200100492
  • 财政年份:
    2020
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
  • 批准号:
    407264
  • 财政年份:
    2019
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
  • 批准号:
    18K18240
  • 财政年份:
    2018
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
  • 批准号:
    17K12379
  • 财政年份:
    2017
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
  • 批准号:
    17K13937
  • 财政年份:
    2017
  • 资助金额:
    $ 33.98万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
  • 批准号:
    8742767
  • 财政年份:
    2014
  • 资助金额:
    $ 33.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了